| Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (NCT05364073) | ArriVent BioPharma, Inc. | 2022-06-30 |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (NCT05379985) | Revolution Medicines, Inc. | 2022-05-31 |
| WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC (NCT05351320) | Jinming Yu | 2022-04-30 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (NCT05253807) | Incyte Corporation | 2022-04-29 |
| A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (NCT05068102) | Boehringer Ingelheim | 2022-03-03 |
| Tumor-informed MRD for Non-small Cell Lung Cancer (NCT07596433) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-02-18 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (NCT05176483) | Exelixis | 2021-12-14 |
| Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer (NCT05088967) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-12-02 |
| A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). (NCT05141786) | Shanghai Miracogen Inc. | 2021-12-01 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours (NCT05057013) | Cancer Research UK | 2021-11-10 |
| Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer (NCT05100069) | Takeda | 2021-11-01 |
| A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (NCT04908111) | Cancer Research UK | 2021-10-15 |
| A Study of NX-1607 in Adults With Advanced Malignancies (NCT05107674) | Nurix Therapeutics, Inc. | 2021-09-29 |
| Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04921358) | BeiGene | 2021-07-27 |
| Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom (NCT04667312) | AstraZeneca | 2021-06-24 |
| The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients (NCT04909164) | Samsung Medical Center | 2021-06-15 |
| HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NCT04676477) | Daiichi Sankyo | 2021-06-11 |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (NCT04677595) | Novartis Pharmaceuticals | 2021-05-17 |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NCT04763083) | NovalGen Ltd. | 2021-05-14 |
| A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (NCT04832854) | Hoffmann-La Roche | 2021-04-23 |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer (NCT04267237) | Hoffmann-La Roche | 2021-03-31 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer (NCT04844073) | Takeda | 2021-03-08 |
| Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study (NCT04753918) | Taoyuan General Hospital | 2021-03-01 |
| Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC (NCT04905550) | Chongqing University Cancer Hospital | 2021-03-01 |
| Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (NCT04721015) | AbbVie | 2021-02-23 |
| A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device. (NCT04751162) | Hoffmann-La Roche | 2021-02-18 |
| PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) (NCT04524195) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-02-01 |
| Predicting Response to PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging and Clinical Data (NCT05711914) | Centre Hospitalier Universitaire de Nīmes | 2021-01-31 |
| A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (NCT04619797) | Hoffmann-La Roche | 2020-12-15 |
| Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC (NCT07053215) | The First Hospital of Hebei Medical University | 2020-12-01 |
| A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788 (NCT04576208) | Takeda | 2020-11-30 |
| Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) (NCT04563871) | Sehhoon Park | 2020-11-17 |
| A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (NCT04513925) | Hoffmann-La Roche | 2020-08-24 |
| A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors (NCT04424641) | Genmab | 2020-07-15 |
| Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC (NCT04338620) | Tang-Du Hospital | 2020-04-07 |
| An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (NCT04189614) | AbbVie | 2020-02-13 |
| Prospective Clinicogenomic Program (NCT04180176) | Genentech, Inc. | 2019-12-13 |
| A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (NCT04026412) | Bristol-Myers Squibb | 2019-10-08 |
| GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors (NCT04083599) | Genmab | 2019-09-17 |
| Comparison of Two Techniques of Uniportal VATS Lobectomies for Clinical Stage I Non-Small Cell Lung Cancer (NCT03997799) | Pulmonary Hospital Zakopane | 2019-06-10 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (NCT03893955) | AbbVie | 2019-05-21 |
| Osimertinib Study in Indian Patients (NCT03853551) | AstraZeneca | 2019-04-18 |
| A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NCT03693300) | AstraZeneca | 2019-04-16 |
| DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NCT03255083) | Daiichi Sankyo | 2019-04-10 |
| Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (NCT03775486) | AstraZeneca | 2018-12-21 |
| A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (NCT03725475) | AstraZeneca | 2018-11-26 |
| An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT03735628) | Bayer | 2018-10-17 |
| A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors (NCT03708328) | Hoffmann-La Roche | 2018-10-15 |
| Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC (NCT03667820) | University of Texas Southwestern Medical Center | 2018-09-26 |
| The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (NCT03523702) | Montefiore Medical Center | 2018-08-30 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NCT03549000) | Novartis Pharmaceuticals | 2018-07-18 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy (NCT03559647) | Hoffmann-La Roche | 2018-05-30 |
| Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. (NCT03447678) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2018-05-23 |
| A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (NCT03409458) | Promontory Therapeutics Inc. | 2018-04-24 |
| Pulmonary Rehabilitation Before Lung Cancer Resection (NCT02887521) | Alliance for Clinical Trials in Oncology | 2018-02-28 |
| A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients (NCT03407300) | Haining Health-Coming Biotech Co., Ltd. | 2018-02-01 |
| To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC (NCT05169801) | Jiangsu HengRui Medicine Co., Ltd. | 2018-01-25 |
| Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer (NCT03505515) | Bristol-Myers Squibb | 2017-12-07 |
| U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer (NCT03260491) | Daiichi Sankyo | 2017-10-30 |
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348) | Replimune, Inc. | 2017-09-20 |
| Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (NCT03164616) | AstraZeneca | 2017-06-01 |
| A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients (NCT02879617) | Academic Thoracic Oncology Medical Investigators Consortium | 2017-04-04 |
| A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations (NCT03082300) | Astellas Pharma Global Development, Inc. | 2017-03-24 |
| F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer (NCT05468294) | Philogen S.p.A. | 2017-03-09 |
| Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer (NCT02916745) | Concordia Laboratories Inc. | 2017-01-26 |
| A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer (NCT02840994) | Bavarian Nordic | 2016-12-01 |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (NCT02988817) | Genmab | 2016-11-23 |
| A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions (NCT02927340) | Massachusetts General Hospital | 2016-10-01 |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) (NCT02771626) | Calithera Biosciences, Inc | 2016-08-01 |
| A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (NCT02740985) | AstraZeneca | 2016-06-17 |
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) (NCT02698176) | Merck Sharp & Dohme LLC | 2016-05-04 |
| The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation (NCT02820116) | Beijing Haidian Hospital | 2016-05-01 |
| A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02714608) | Tasly Pharmaceuticals, Inc. | 2016-05-01 |
| FDG PET/CT in Lung Cancer Staging (NCT02738398) | Abramson Cancer Center at Penn Medicine | 2016-04-01 |
| A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer (NCT02662634) | GU Research Network, LLC | 2016-03-01 |
| A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (NCT02588261) | Astellas Pharma Global Development, Inc. | 2016-02-11 |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers (NCT02639026) | Abramson Cancer Center at Penn Medicine | 2016-01-26 |
| Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases (NCT02132598) | Liza Villaruz, MD | 2015-12-01 |
| Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NCT02642939) | Check, Jerome H., M.D., Ph.D. | 2015-12-01 |
| Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy (NCT02608528) | Abramson Cancer Center at Penn Medicine | 2015-10-22 |
| Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer (NCT02521051) | Massachusetts General Hospital | 2015-09-28 |
| Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM (NCT02555007) | Assistance Publique Hopitaux De Marseille | 2015-08-26 |
| Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer (NCT02448992) | Chang Gung Memorial Hospital | 2015-08-01 |
| the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs (NCT02603003) | Shanghai University of Traditional Chinese Medicine | 2015-06-01 |
| Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC (NCT02667743) | Shanghai Yizhong Pharmaceutical Co., Ltd. | 2015-05-01 |
| Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT (NCT02456246) | University Health Network, Toronto | 2015-05-01 |
| Improving Resection Rates Among African Americans With NSCLC (NCT01885455) | Wake Forest University Health Sciences | 2015-04-23 |
| The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer (NCT02380196) | Abramson Cancer Center at Penn Medicine | 2015-03-01 |
| A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (NCT02352948) | AstraZeneca | 2015-01-13 |
| A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) (NCT02364362) | Jiangsu HengRui Medicine Co., Ltd. | 2015-01-01 |
| Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1 (NCT07036016) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2015-01-01 |
| A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) (NCT02356991) | Jiangsu HengRui Medicine Co., Ltd. | 2014-12-01 |
| Selumetinib in Combination With Gefitinib in NSCLC Patients (NCT02025114) | National Taiwan University Hospital | 2014-09-01 |
| Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea (NCT02196675) | Ethicon Endo-Surgery | 2014-07-01 |
| Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT02221739) | NYU Langone Health | 2014-07-01 |
| A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (NCT02066636) | Bristol-Myers Squibb | 2014-04-09 |
| A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations (NCT02113813) | Astellas Pharma Global Development, Inc. | 2014-04-09 |
| Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer (NCT02111681) | Memorial Sloan Kettering Cancer Center | 2014-04-01 |